The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 6 A GCS values for patient with a favorable neurological outcome (n = 21) throughout study duration. B Comparison between GCS values for patient with a favorable neurological outcome (n = 21) throughout study duration

From: The use of dexamethasone therapy for conservative management of chronic subdural hematomas: a question about efficacy and safety

GCS	Day 1 (%)	Day 14 (%)	1 month (%)	3 months (%)	6 months (%)
13	8 (38.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
14	10 (47.6)	11 (52.4)	6 (28.6)	1 (4.8)	0 (0.0)
15	3 (14.3)	10 (47.6)	15 (71.4)	20 (95.2)	21 (100.0)

Measurements	Chi-square test	p-value
Day 1 vs. Day 14	11.817	0.003*
Day 1 vs. 1 M	17.000	< 0.001**
Day 1 vs. 3 M	27.929	< 0.001**
Day 1 vs. 6 M	31.500	< 0.001**
Day 14 vs. 1 M	1.581	0.209
Day 14 vs. 3 M	9.450	0.002*
Day 14 vs. 6 M	12.317	< 0.001**
1 M vs. 3 M	2.743	0.098
1 M vs. 6 M	4.861	0.028*
3 M vs. 6 M	0.477	0.490

Using: Chi-square test
GCS Glasgow Coma Scale, n number of patients, M months after protocol initiation
p-value > 0.05 is insignificant, *p-value < 0.05 is significant, **p-value < 0.001 is highly significant

Back to article page